Norditropin SimpleXx
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prader-Willi Syndrome
Conditions
Prader-Willi Syndrome
Trial Timeline
Apr 1, 2005 → Mar 1, 2010
NCT ID
NCT00372125About Norditropin SimpleXx
Norditropin SimpleXx is a pre-clinical stage product being developed by Novo Nordisk for Prader-Willi Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00372125. Target conditions include Prader-Willi Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00372125 | Pre-clinical | Completed |
Competing Products
18 competing products in Prader-Willi Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Octreotide + Placebo | Novartis | Pre-clinical | 23 |
| somatropin - GH naïve pediatric cohort + somatropin - GH treated cohort + somatropin - adult cohort | Pfizer | Phase 3 | 76 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 2 | 49 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 2 | 49 |
| RGH-706 + Placebo | Richter Gedeon | Phase 2 | 49 |
| Carbetocin | Acadia Pharmaceuticals | Phase 3 | 72 |
| Carbetocin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |
| DCCR | Soleno Therapeutics | Phase 3 | 72 |
| DCCR + DCCR + Placebo for DCCR | Soleno Therapeutics | Phase 3 | 72 |
| Pitolisant | Harmony Biosciences | Phase 3 | 72 |
| Pitolisant tablet | Harmony Biosciences | Phase 3 | 72 |
| Pitolisant oral tablets + Placebo oral tablet | Harmony Biosciences | Phase 2 | 47 |
| DCCR | Soleno Therapeutics | Phase 3 | 72 |
| VYKAT XR | Soleno Therapeutics | Pre-clinical | 18 |
| DCCR + Placebo for DCCR | Soleno Therapeutics | Phase 3 | 72 |
| NNZ-2591 | Neuren Pharmaceuticals | Phase 2 | 47 |
| BMB-101 + Placebo | Bright Minds Biosciences | Phase 2 | 47 |
| ARD-101 | Aardvark Therapeutics | Phase 2 | 44 |